# A Rare Case of Osmotic Demyelination Syndrome in Advanced Pancreatic Adenocarcinoma Without Hyponatremia

**Authors:** Konstantinos Baronos, Muhammad Memon

PMC · DOI: 10.7759/cureus.80406 · Cureus · 2025-03-11

## TL;DR

A rare case of osmotic demyelination syndrome is reported in a cancer patient without low sodium levels.

## Contribution

This case highlights ODS occurrence in cancer patients without hyponatremia, emphasizing new risk factors.

## Key findings

- ODS occurred in a pancreatic cancer patient with normal sodium levels.
- Nutrient deficiencies, hypokalemia, and hyperglycemia contributed to ODS in this case.
- The case underscores the need for increased awareness of ODS in malignancy patients.

## Abstract

Osmotic demyelination syndrome (ODS) is a rare neurological disease involving myelin loss in the central nervous system and is traditionally linked with abrupt correction of hyponatremia. In the absence of hyponatremia, ODS can occur if there are other risk factors such as malignancy, malnutrition, and metabolic disturbances. We describe a 52-year-old male with advanced pancreatic adenocarcinoma and liver metastases who presented with confusion, falls, bilateral leg oedema, hyperglycemia and hypokalemia. Initial imaging was negative for intracranial pathology but positive for pancreatic and hepatic malignancy. The patient's condition deteriorated despite intravenous insulin and potassium, and a brain MRI was positive for central pontine ODS without evidence of metastatic disease. Sodium levels were within normal limits on hospitalisation. A multi-disciplinary team deemed the malignancy inoperable, and the patient was transferred to palliative care and died three weeks post-discharge. This case illustrates the multifactorial aetiology of ODS in cancer patients, with a contribution from malignancy-related nutrient deficiencies, hypokalemia, and hyperglycemia despite normal sodium. Current literature identifies oligodendrocyte susceptibility to energy deficiency in cancer as a predisposition to ODS. This report highlights the significance of heightened awareness of ODS in malignancy, even in the absence of hyponatremia, and calls for further research into its pathophysiological basis as well as management.

## Linked entities

- **Chemicals:** sodium (PubChem CID 5360545), potassium (PubChem CID 813), insulin (PubChem CID 70678557)
- **Diseases:** pancreatic adenocarcinoma (MONDO:0006047)

## Full-text entities

- **Diseases:** energy deficiency (MESH:D011502), metabolic disturbances (MESH:D024821), nutrient deficiencies (MESH:D007153), Hyponatremia (MESH:D007010), confusion (MESH:D003221), hypokalemia (MESH:D007008), neurological disease (MESH:D020271), hyperglycemia (MESH:D006943), Pancreatic Adenocarcinoma (MESH:D010190), metastases (MESH:D009362), liver (MESH:D017093), malnutrition (MESH:D044342), leg oedema (MESH:C536897), ODS (MESH:D003711), cancer (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11984518/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11984518/full.md

## References

18 references — full list in the complete paper: https://tomesphere.com/paper/PMC11984518/full.md

---
Source: https://tomesphere.com/paper/PMC11984518